On Oct. 6, 2021, Vaxart announced that it had begun recruiting subjects for its Phase II COVID-19 oral tablet vaccine clinical trial.

Vaxart expects to begin dosing the first of 96 U.S. subjects, split evenly between COVID-19 naïve and mRNA vaccinated subjects, later this month. 

The company’s Phase II COVID-19 program will also include countries outside of the United States, starting with a trial in India that is expected to begin later this year.